Literature DB >> 7679100

Enzymatic analysis of two HIV-1 reverse transcriptase mutants with mutations in carboxyl-terminal amino acid residues conserved among retroviral ribonucleases H.

S Volkmann1, B M Wöhrl, M Tisdale, K Moelling.   

Abstract

The reverse transcriptase (RT) of HIV-1 has been mutagenized within the carboxyl-terminal domain which harbors the RNase H. Two amino acids highly conserved among all 14 known RT sequences but not in the bacterial RNase H have been mutagenized resulting in the mutant proteins N494D and Q475E. They were expressed as recombinant proteins, purified, and analyzed for their in vitro properties in comparison to the p66 homodimeric wild-type and a previously described H539N mutant. The N494D mutant closely resembles the wild-type RNase H, exhibits an endonuclease activity and a processive RNase H activity, gives rise to small RNA hydrolysis products, and acts in concert with the RT. The Q475E mutant is more defective and resembles the H539N mutant, exhibits a retarded endonuclease activity and an impaired 3'-->5' processive RNA cleavage activity, gives rise to predominantly larger RNA hydrolysis products, is less processive in the presence of competitor substrate, and is defective in its ability to hydrolyze the polypurine tract and homopolymeric hybrids. Short homopolymeric stretches cause a pausing of the RT of wild-type and mutants which results in a coordinated action of the RNase H. Pausing of the RT correlates with RNase H cleavages about 20 nucleotides behind the point of synthesis. The defects of the mutant enzymes can be interpreted on the basis of the known crystallography data.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7679100

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  14 in total

1.  Replication of phenotypically mixed human immunodeficiency virus type 1 virions containing catalytically active and catalytically inactive reverse transcriptase.

Authors:  J G Julias; A L Ferris; P L Boyer; S H Hughes
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

2.  Mechanism for nucleoside analog-mediated abrogation of HIV-1 replication: balance between RNase H activity and nucleotide excision.

Authors:  Galina N Nikolenko; Sarah Palmer; Frank Maldarelli; John W Mellors; John M Coffin; Vinay K Pathak
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-31       Impact factor: 11.205

3.  Quantitative analysis of RNA cleavage during RNA-directed DNA synthesis by human immunodeficiency and avian myeloblastosis virus reverse transcriptases.

Authors:  J J DeStefano; L M Mallaber; P J Fay; R A Bambara
Journal:  Nucleic Acids Res       Date:  1994-09-11       Impact factor: 16.971

4.  Reversion of a Moloney murine leukemia virus RNase H mutant at a second site restores enzyme function and infectivity.

Authors:  S W Blain; W A Hendrickson; S P Goff
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

5.  An unusual mechanism of self-primed reverse transcription requires the RNase H domain of reverse transcriptase to cleave an RNA duplex.

Authors:  H L Levin
Journal:  Mol Cell Biol       Date:  1996-10       Impact factor: 4.272

6.  Crystal structure of HIV-1 reverse transcriptase in complex with a polypurine tract RNA:DNA.

Authors:  S G Sarafianos; K Das; C Tantillo; A D Clark; J Ding; J M Whitcomb; P L Boyer; S H Hughes; E Arnold
Journal:  EMBO J       Date:  2001-03-15       Impact factor: 11.598

7.  In vitro analysis of human immunodeficiency virus type 1 minus-strand strong-stop DNA synthesis and genomic RNA processing.

Authors:  M D Driscoll; M P Golinelli; S H Hughes
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

8.  The "Connection" Between HIV Drug Resistance and RNase H.

Authors:  Krista A Delviks-Frankenberry; Galina N Nikolenko; Vinay K Pathak
Journal:  Viruses       Date:  2010-07-01       Impact factor: 5.048

9.  Variations in reverse transcriptase and RNase H domain mutations in human immunodeficiency virus type 1 clinical isolates are associated with divergent phenotypic resistance to zidovudine.

Authors:  Michel Ntemgwa; Mark A Wainberg; Maureen Oliveira; Daniela Moisi; Richard Lalonde; Valeria Micheli; Bluma G Brenner
Journal:  Antimicrob Agents Chemother       Date:  2007-08-27       Impact factor: 5.191

10.  Inhibition of HIV-1 reverse transcription by triple-helix forming oligonucleotides with viral RNA.

Authors:  S Volkmann; J Jendis; A Frauendorf; K Moelling
Journal:  Nucleic Acids Res       Date:  1995-04-11       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.